Nucleome Therapeutics

Nucleome Therapeutics is a pioneering immunology company tackling the root causes of immune-mediated inflammatory diseases by decoding the non-coding human genome. Its core innovation is a transformative 3D genomics technology that provides unprecedented precision and scale in linking genetic variants in regulatory regions to their target genes, enabling the discovery of novel disease mechanisms and drug targets invisible to conventional approaches. The company is using this platform to build a rich data atlas of immune system dysregulation and a corresponding pipeline of first-in-class therapeutics. Headquartered in Oxford, UK, Nucleome is a private, pre-clinical stage company positioned at the intersection of human genetics, functional genomics, and drug discovery.

Proprietary 3D genomics platform that maps chromatin interactions in immune cells with high precision and scale, linking non-coding genetic variants to their target genes to identify causal disease mechanisms and novel therapeutic targets.

Nucleome operates in the competitive field of functional genomics and genetics-driven drug discovery. It faces competition from large pharma internal efforts, other biotechs using CRISPR screening or massive parallel reporter assays, and academic consortia. Its claimed differentiation is the precision and industrial scale of its 3D genomic mapping specifically in immune cells.